Can evantumumab/Carzoline completely cure the disease?

Amivantamab (amivantamab) is an innovative bispecific antibody drug that has received widespread attention in the field of tumor treatment in recent years. The original intention of its research and development is not to achieve a "complete cure", but to control tumor progression by blocking two key pathways, EGFR and MET, to delay disease progression and provide patients with new treatment options when drug resistance mechanisms emerge. In the context of medical treatment becoming a global trend, the application of Carestream has brought new hope to patients with EGFR exon 20 insertion mutation non-small cell lung cancer. In the past, these patients lacked effective targeted treatment options and often had to rely on chemotherapy, with limited efficacy and tolerability.

However, regarding the issue that patients are most concerned about "can it be cured?", the current scientific conclusions are still conservative and rational. The complexity of cancer lies in the fact that it is not a disease driven by a single pathway. Even if EGFR and MET signals are blocked, tumors may still gain growth advantages through other pathways, leading to drug resistance or recurrence. Therefore, the positioning of amivantamab is more to "extend survival, improve symptoms, and improve quality of life" rather than to completely eliminate cancer. It is worth noting that some patients can indeed achieve significant disease remission after using Carestream, and even see the lesions shrink on imaging. This was almost impossible to achieve in the past when there was a lack of effective targeted drugs. This is also the core reason why it was approved by overseas authorities.

The possibility of combining evantumumab with other drugs, including chemotherapy, immune checkpoint inhibitors or other targeted drugs, is being explored in order to overcome the limitations of monotherapy. If these combined strategies are further validated, they may promote overall improvements in patient prognosis in the future. From the patient's perspective, the significance of Carestream is that it provides a new treatment idea. It does not represent the "end", but an important link in the management of chronic cancer.

Reference materials:https://www.rybrevant.com/